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Introduction 
Magmaris® (Biotronik AG, Bülach, Switzerland) is a magnesium-
based scaffold that has been successfully tested in 184 patients 
enrolled in the BIOSOLVE-II and BIOSOLVE-III studies1,2. After 
gaining CE certification in June 2016, it was paramount to test 
this device in clinical routine to ensure a safe roll-out of this 
technology.
Editorial, see page 1307
Methods
BIOSOLVE-IV is an international, single-arm, multicentre reg-
istry conducted in 86 centres. The first patient was enrolled in 
September 2016. Inclusion and exclusion criteria and endpoints 
are listed on ClinicalTrials.gov (NCT02817802).
Clinical follow-up was scheduled at six and 12 months, and 
annually up to five years (telephone follow-ups were permitted). 
The study was performed according to the Declaration of Helsinki 
and ISO14155:2011, was approved by the ethics committees, 
and all patients provided written informed consent. Monitoring 
encompassed a minimum of 25% random subjects per centre; 
an angiographic core laboratory assessed endpoint-related events 
and device failures. All potential device-related events were adju-
dicated by an independent clinical events committee member. In 
case of disagreement with a study site, the case was reviewed by 
a second clinical events committee member.
Magmaris has been described previously1,2. Predilatation using 
a non-compliant balloon with a 1:1 balloon-to-artery ratio was 
mandatory. The balloon should expand fully and the residual ste-
nosis before Magmaris implantation ought to be <20%. The scaf-
fold implantation ought to follow the recommendation of the 
instructions for use and the consensus letter of Fajadet et al3. Post-
dilatation with a non-compliant balloon at high pressure (>16 atm) 
was recommended. Dual antiplatelet therapy (DAPT) was recom-
mended for at least six months.
The sample size of 2,054 patients was calculated based on the 
null hypothesis that Magmaris has a 12-month probable or defi-
nite scaffold thrombosis rate of ≥1.49%. Endpoint analyses were 
planned after every 200 subjects reaching the primary endpoint.
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Results
This publication refers to the first 400 patients with 425 lesions 
enrolled. Patient age ranged from 29 to 86 years (Table 1); 
63 patients (15.8%) presented with non-ST-elevation myocardial 
infarction (NSTEMI) (Figure 1). Predilatation and post-dilatation 
were performed in nearly all patients. Magmaris could not be 
implanted in three patients (0.8%) (Table 2).
Concerning 12-month follow-up data, two patients had died of 
cancer, six visits were missed and one patient withdrew consent 
(compliance of 98.2%, 390/397); 76.8% (298/388) were on DAPT. 
The primary endpoint, target lesion failure (TLF) at 12 months, 
was 4.3% (n=17) (Figure 2). All had clinically driven target lesion 
revascularisation (TLR), of whom three (0.8%) had additional tar-
get vessel myocardial infarction (TV-MI).
One definite scaffold thrombosis (0.3%) occurred on post-pro-
cedure day 10. The patient was admitted with NSTEMI and severe 
three-vessel coronary artery disease. First, the occluded circum-
flex artery was treated using a non-study stent. Four days later, 
the index procedure with the Magmaris scaffold was performed 
to treat a stenosis in a heavily calcified right coronary artery. 
Thereafter, a minimally invasive direct coronary artery bypass 
graft (left internal mammary artery to ramus interventricularis 
anterior) was intended and hence DAPT was interrupted five days 
after the index procedure. Five days later, a scaffold thrombosis 
occurred that led to a TV-MI and required a TLR. The patient was 
alive at 12 months.
Discussion
This pre-specified interim analysis of the first 400 patients enrolled 
in the BIOSOLVE-IV registry confirmed the favourable safety 
outcomes of the BIOSOLVE-II and BIOSOLVE-III trials with low 
TLF rates at 12 months comparable to new-generation permanent 
drug-eluting stents (DES), no cardiac death and only one scaffold 
thrombosis that occurred after DAPT interruption.
Comparing outcomes to the BIOSOLVE-II and BIOSOLVE-III 
studies, in BIOSOLVE-IV, baseline characteristics were similar 
with relatively simple lesions. The only relevant difference was 
the inclusion of 15.8% NSTEMI patients who were excluded in 
the precursor studies1,2. The rate of TLF was also similar, albeit 
clinically driven TLR was slightly higher in BIOSOLVE-IV. One 
definite scaffold thrombosis occurred in our series, which is the 
first definite scaffold thrombosis in the 584 patients published to 
date1,2. It occurred at day 10 after DAPT cessation in a patient with 
severe three-vessel disease after a staged procedure, emphasising 
that DAPT in the early days after Magmaris implantation is as 
important as after DES implantation.
Our outcomes are also within the range of the objective per-
formance criteria for new-generation stents as postulated by the 
Table 1. Baseline clinical and lesion characteristics.
Patients N=400
Mean age, years 62.0±11.0 
Male 294 (73.5)
Hypertension 255 (63.8)
Diabetes 78 (19.5)
Insulin-dependent 15 (19.2)
History of myocardial infarction 73 (18.3)
Previous percutaneous coronary intervention 93 (23.3)
Lesions* N=425
Lesion length, mm 14.5±4.1 
Reference vessel diameter, mm  3.3±0.3 
Diameter stenosis, % 82.3±10.4 
AHA/ACC classification type B2/C 75 (17.7)
Bifurcation lesion 24 (5.6)
Data are shown as mean±SD or n (%). * per site assessment
Table 2. Procedural characteristics.
N=425
Predilatation performed 423 (99.5)
Maximum pressure applied, atm, N=545 13.6±3.2 
Scaffold sizes
3.0×15 mm/×20 mm/×25 mm 89 (20.5)/ 89 (20.5)/ 53 (12.2)
3.5×15mm/×20 mm/×25 mm 69 (15.9)/ 80 (18.4)/ 54 (12.4)
Maximum pressure applied, atm, N=431 13.9±2.8 
Post-dilatation performed 403 (94.8)
Maximum pressure applied, atm, N=466 17.0±3.5 
Device success, N=439 stents 422 (96.1)
Procedure success, N=400 patients 394 (98.5)
Data are shown as mean±SD or n (%). Device success was defined as a final diameter 
stenosis of <30% using the assigned device only, successful delivery of the scaffold, 
appropriate scaffold deployment, and successful removal of the device. Procedure success 
was defined as a final diameter stenosis <30% without the occurrence of death, 
myocardial infarction, or repeat target lesion revascularisation during the hospital stay.
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Figure 1. Ischaemic status at baseline and follow-up. NSTEMI: 
non-ST-elevation myocardial infarction
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BIOSOLVE-IV registry
ESC/EAPCI’s task force, namely 2.91% TLR (IQR 1.67-5.94) 
and 0.47% definite stent thrombosis (IQR 0.28–0.72) at 9- to 
12-month follow-up4.
Limitations 
BIOSOLVE-IV has limitations inherent to observational registries.
Conclusion
This preliminary analysis after 400 patients enrolled in the 
BIOSOLVE-IV real-world registry confirms the safe roll-out of 
a magnesium-based bioresorbable scaffold into clinical practice 
with low TLF rates and only one scaffold thrombosis after DAPT 
cessation.
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Figure 2. Kaplan-Meier estimates of clinical outcomes up to 12 months. A) TLF. B) Cardiac death. C) TV-MI. D) Clinically driven TLR. 
E) Clinically driven TVR. F) Definite and probable scaffold thrombosis. TLF: target lesion failure; TLR: target lesion revascularisation; 
TV-MI: target vessel myocardial infarction (periprocedural MI were adjudicated using SCAI definitions and spontaneous MI using the 
extended historical definitions); TVR: target vessel revascularisation
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Impact on daily practice
This registry represents the largest clinical experience with the 
sirolimus-eluting magnesium-based Magmaris BRS to date. It 
provides additional assurance on the safety and performance 
of the device with low TLF and stent thrombosis rates. DAPT 
cessation prior to six months should be strongly discouraged.
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